You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,624,003


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,624,003
Title:Methods for preparation of antibody-maytansinoid conjugates
Abstract: This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.
Inventor(s): Kellogg; Brenda A. (Medford, MA), Singh; Rajeeva (Framingham, MA), Chari; Ravi V. J. (Newton, MA)
Assignee: ImmunoGen, Inc. (Waltham, MA)
Application Number:12/793,175
Patent Claims:1. A process for preparing a purified conjugate in a solution, wherein the conjugate comprises a maytansinoid molecule linked to an antibody, the process comprising the steps of: (a) contacting a maytansinoid molecule comprising a thiol group with a bifunctional linker reagent to covalently attach the linker to the maytansinoid molecule, wherein an excess of maytansinoid molecule relative to the bifunctional linker reagent is used, and thereby prepare an unpurified first mixture comprising the maytansinoid molecule having linkers hound thereto, (b) conjugating an antibody to the maytansinoid molecule having linkers bound thereto by reacting the unpurified first mixture with the antibody in a solution having a pH from about 4 to about 9 to prepare a second mixture, and (c) subjecting the second mixture to tangential flow filtration, dialysis, gel filtration, adsorptive chromatography, selective precipitation or a combination thereof to thereby prepare the purified conjugate.

2. The process of claim 1, wherein the second mixture in step (b) is substantially free of undesired cross-linked, hydrolyzed species formed due to intra-molecular or inter-molecular reactions.

3. The process of claim 1, wherein the maytansinoid molecule is DM1.

4. The process of claim 1, wherein the maytansinoid molecule is DM4.

5. The process of claim 1, wherein the antibody is a monoclonal antibody.

6. The process of claim 1, wherein the antibody is a human or a humanized monoclonal antibody.

7. The process of claim 1, wherein the antibody is MY9, anti-B4, C242, or an antibody that binds to an antigen selected from the group consisting of EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFR, EGFRvIII, HER2, HER3, mesothelin, cripto, alpha.sub.vbeta.sub.3, alpha.sub.vbeta.sub.5, and alpha.sub.vbeta.sub.6 integrin.

8. The process of claim 6, wherein the human or the humanized antibody is huMy9-6, huB4, huC242, huN901, DS6, CNTO 95, B-B4, trastuzumab, pertuzumab, bivatuzumab, sibrotuzumab, rituximab, or a human or humanized antibody that binds to an antigen selected from the group consisting of EphA2 receptor CD38, and IGF-IR.

9. The process of claim 1, wherein the linker is a cleavable or a non cleavable linker.

10. The process of claim 1, wherein the pH of the solution in step (b) is from about 5 to about 8.7.

11. The process of claim 1, wherein the pH of the solution in step (b) is from about 6.5 to about 8.5.

12. The process of claim 1, wherein the process further comprises the step of quenching the excess maytansinoid in the unpurified first mixture with a quenching reagent between steps (a) and (b).

13. The process of claim 12, wherein the quenching reagent is selected from the group consisting of 4-malcimidobutyric acid, 3-maleimidopropionic acid, N-ethylmaleimide, iodoacetamide, and iodoacetamidopropionic acid.

Details for Patent 8,624,003

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. RITUXAN rituximab Injection 103705 11/26/1997 ⤷  Try a Trial 2029-06-03
Idec Pharmaceuticals Corp. RITUXAN rituximab Injection 103737 02/19/2002 ⤷  Try a Trial 2029-06-03
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 09/25/1998 ⤷  Try a Trial 2029-06-03
Genentech, Inc. HERCEPTIN trastuzumab For Injection 103792 02/10/2017 ⤷  Try a Trial 2029-06-03
Genentech, Inc. PERJETA pertuzumab Injection 125409 06/08/2012 ⤷  Try a Trial 2029-06-03
Genentech, Inc. RITUXAN HYCELA rituximab and hyaluronidase human Injection 761064 06/22/2017 ⤷  Try a Trial 2029-06-03
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.